The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net revenues | -20,107,649 | 21,667,212 | - |
| Cost of net revenues | -18,848,465 | 20,237,807 | - |
| Gross profit (loss) | -1,259,184 | 1,429,405 | - |
| General and administrative | -61,336,734 | 66,205,669 | - |
| Sales and marketing | -252,347 | 1,212,347 | - |
| Depreciation and amortization | -2,051,638 | 2,408,462 | - |
| Total operating expenses | -63,640,719 | 69,826,478 | - |
| Loss from operations | 62,381,535 | -68,397,073 | - |
| Interest expense, net | -1,631,158 | 3,703,837 | - |
| Gain on extinguishment of vendor obligation | 1,613,543 | -1,353,663 | - |
| Settlement fees | 13,000 | - | - |
| Other income | 65,738 | 33,002 | - |
| Total other expense, net | 3,297,439 | -5,024,498 | - |
| Net loss before income taxes | 65,678,974 | -73,421,571 | - |
| Net loss | 65,678,974 | -34,318,204 | -39,103,367 |
| Prepaid expenses | -65,001 | - | 65,001 |
| Deposits | - | -65,000 | 0 |
| Allowances for credit losses | -171,884 | 65,128 | 200,454 |
| Amortization of debt discount | 1,045,836 | 406,371 | 33,411 |
| Stock-based compensation | -53,081,063 | 25,730,184 | 28,708,643 |
| Amortization | -1,960,232 | 763,065 | 1,526,129 |
| Accounts receivable, net | 1,308,459 | -996,923 | -362,911 |
| Other assets | - | 20,999 | -332 |
| Inventories, net | 2,100,881 | -1,539,243 | -487,465 |
| Accounts payable | -2,629,701 | 960,046 | 3,141,897 |
| Accrued expenses and other liabilities | -2,208,196 | 1,152,507 | 1,145,749 |
| Operating lease liabilities, net | -71,175 | 62,035 | -5,720 |
| Due from / to related parties, net | 425,289 | -134,977 | -61,112 |
| Depreciation | -91,407 | 39,731 | 79,538 |
| Gain on extinguishment of vendor obligation | 1,613,543 | -1,353,663 | - |
| Net cash used in operating activities | 1,148,647 | -1,135,329 | -3,426,447 |
| Proceeds from revolving line of credit | - | 2,924,000 | 17,146,000 |
| Investments in capitalized software | -421,046 | 221,085 | 405,059 |
| Proceeds from term loan | - | 228,448 | 703,366 |
| Cash acquired in business combinations | - | - | 0 |
| Proceeds from common stock issued pursuant to equity purchase agreement | - | 2,271,065 | 567,722 |
| Net cash used in investing activities | 421,046 | -221,085 | -405,059 |
| Proceeds from promissory note | -615,000 | 0 | 615,000 |
| Repayment of seller promissory note | 0 | - | - |
| Proceeds from revolving line of credit | 0 | - | - |
| Proceeds from common stock issued pursuant to ipo | - | 0 | 4,000,000 |
| Proceeds from merchant cash advance | 365,613 | -599,770 | 234,157 |
| Proceeds from common stock issued pursuant to public offering | -4,534,053 | 4,534,053 | - |
| Offering costs | 1,471,141 | -262,643 | -1,208,498 |
| Repayment of promissory note | -100,390 | 0 | 137,141 |
| Repayment of revolving line of credit | -22,483,984 | 3,930,015 | 18,697,494 |
| Proceeds from convertible notes | 6,002,500 | - | - |
| Repayment of merchant cash advance | 90,281 | - | - |
| Founders initial contribution | - | - | 0 |
| Repayment of term loan | 2,104,557 | - | - |
| Net cash provided by financing activities | -4,760,864 | 5,165,138 | 3,223,112 |
| Net change in cash and cash equivalents | -3,191,171 | - | - |
| Net change in cash and cash equivalents | -3,191,171 | 3,808,724 | -608,394 |
| Cash and cash equivalents at beginning of period | 4,228,666 | 1,028,336 | - |
| Cash and cash equivalents at end of period | 51,730 | 4,228,666 | - |
Wellgistics Health, Inc. (WGRX)
Wellgistics Health, Inc. (WGRX)